Related Experiment Videos
Choosing an atypical antipsychotic.
1New York University School of Medicine, New York, USA. sussman01@aol.com
International Clinical Psychopharmacology
|February 7, 2003
Summary
Quetiapine offers a favorable safety profile among atypical antipsychotics, showing fewer extrapyramidal symptoms and a neutral effect on weight. This makes quetiapine an attractive option for psychosis treatment with high patient satisfaction.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Therapeutics
Background:
- Atypical antipsychotics exhibit diverse pharmacological profiles affecting tolerability and safety.
- Extrapyramidal symptoms (EPS) and weight gain are common adverse effects of many antipsychotics.
Purpose of the Study:
- To compare the safety and tolerability profile of quetiapine with other antipsychotics.
- To evaluate quetiapine's effects on extrapyramidal symptoms, prolactin levels, and body weight.
Main Methods:
- Comparative analysis of pharmacological profiles.
- Review of clinical data on adverse effects and patient outcomes.
Main Results:
- Quetiapine demonstrates a lower incidence of EPS compared to haloperidol and risperidone.
- Quetiapine treatment is associated with reduced or normalized serum prolactin levels.
- Quetiapine exhibits a neutral or normalizing effect on body weight and a favorable safety profile requiring no routine monitoring.
Conclusions:
- Quetiapine presents a favorable safety profile, improved tolerability, and high patient satisfaction.
- Its efficacy in reducing psychosis, combined with a low risk of EPS and weight gain, makes it a valuable treatment option.